Computer Intuition is a profound departure from previous drug discovery methods.- Greg Bennett, CBCD
Rochester, NY (PRWEB) November 27, 2013
Rational Drug Design, which uses computers in designing new drug entities that bind with specific targets, did not resolve the productivity crisis in pharmaceutical R&D. “The current target based drug design approach is incomplete because most of the drugs developed by structure guided approaches have been shown to have serious toxic side effects.” This is according to a study published on October 14, 2009 in the European Journal of Pharmacology (2).
Furthermore, Jack Scannell, an analyst at Sanford C. Bernstein who covers European pharma said, “Only a minority of the most innovative drugs had their origins in target-based drug discovery; 17 out of 50. And of these 17, two drugs were eventually approved for indications that were entirely different to those that were intended at the start of the target based search.” The article was published on March 28, 2012 on Forbes.com (3).
The problem, however, is not computers. There are definite benefits in computer-aided drug design. But, in rational drug design, computers only process chemical information. They do not process biological information. In rational drug design, computers are a wonderful tool, but they are only as good as the intuition of the scientists that enter the input and interpret the output. The CBCD believes that today, the limiting factor in pharmaceutical R&D, and the cause of the productivity crisis, is the intuition of these scientists.
Let’s quantify intuition with the following measure. An increase in intuition is any increase in the foresight of the scientists. Or, in simple terms, the more scientists can look into the future, the better the scientist’s intuition is. Another example: Take two scientists. The one who says to the other ten years after the fact, “you were right” has less foresight, and less intuition.
Computer Intuition enhances scientific intuition. That is, it increases the scientists’ foresight and helps them make better, more accurate predictions.
“The following is a description of one prospective application of Computer Intuition. In 1995, Frederiksen published a paper entitled: Diagnostic Imaging in Dental Implantology. At the time, Frederiksen was one of the world leading experts on the subject. To test the predictive power of the Computer Intuition analysis, Almog and Heisler from the University of Rochester devised a test. They conducted a Medline search for papers published between 1980 and 1996 using keywords relevant to the subject of diagnostics, imaging, and dental implantology. The search identified 34 papers. The content of these papers was analyzed with Computer Intuition. The analysis produced three ideas. Two ideas were identical to the main conclusions described in Frederiksen’s paper. This, by itself, was an impressive achievement. By using Computer Intuition, Almog and Heisler duplicated the results of a world leading expert quickly and inexpensively. However, while it took Frederiksen decades to build his expertise, Almog and Heisler acquired similar expertise within weeks. The third idea suggested a new technology. This technology was not mentioned in Frederiksen’s paper. The three ideas were published in 1997 (1).”
"Computer Intuition is a profound departure from previous drug discovery methods. Rational drug design, or computational R&D, is a system that works in the chemical sphere. They process chemical information. In contrast, CI operates in the biological sphere." – Greg Bennett, CBCD
The CBCD invites pharmaceutical executives to contact the Center at info(at)cbcd(dot)net or phone 585-250-9999 to learn how Computer Intuition can be utilized to enhance and further their firms’ R&D goals.
(1) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
(2) Rational drug design. Published on October 14, 2009.
(3) The Drug Industry's Blind Alley. Published on March 28, 2012.
The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.
The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.